免疫反应、炎症及肿瘤免疫相关细胞因子/趋化因子在黑色素瘤进展中的作用
研究基于TCGA黑色素瘤数据估算免疫细胞亚群比例,分析细胞因子/趋化因子表达与免疫亚群及患者生存的关联,并在独立队列中验证TIL评分与预后的相关性。结果显示IL-12A、IFNG、IL-10及CXCL9、CXCL10与PDCD1、CTLA-4、CD8+ T细胞正相关,IFN-γ和TGFB1高表达及CD8+ T细胞高表达与总生存改善相关,brisk TIL评分与黑色素瘤特异性生存改善相关。
要点
- IL-12A、IFNG、IL-10及CXCL9、CXCL10与PDCD1、CTLA-4、CD8+ T细胞正相关,与肿瘤纯度负相关。
- IFN-γ和TGFB1高表达与总生存改善相关,趋化因子无此关联。
- CD8+ T细胞高表达与总生存改善相关(HR=0.06,95%CI 0.01-0.35,P=0.002)。
核心结论
- 特定肿瘤细胞因子/趋化因子表达是黑色素瘤免疫反应的重要生物标志物。
研究设计与样本
- 基于TCGA黑色素瘤数据估算免疫细胞亚群比例,分析细胞因子/趋化因子表达与亚群及生存的关联,并在独立队列中评估TIL评分与预后的相关性。
主要发现
- RNA测序估算的T细胞亚群与病理学家判定的TIL评分一致性良好。
- IL-12A、IFNG、IL-10及CXCL9、CXCL10表达与PDCD1、CTLA-4、CD8+ T细胞正相关,与肿瘤纯度负相关(Bonferroni校正P<0.05)。
- 多变量分析中,IFN-γ和TGFB1高表达与总生存改善相关,趋化因子无此关联。
- CD8+ T细胞高表达与总生存改善相关(HR=0.06,95%CI 0.01-0.35,P=0.002)。
- brisk TIL评分患者黑色素瘤特异性生存优于nonbrisk评分(HR=0.51,95%CI 0.27-0.98,P=0.0423)。
临床怎么用
- 特定肿瘤细胞因子/趋化因子表达及TIL评分可用于评估黑色素瘤免疫反应状态和预后风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To investigate the role of tumor cytokines/chemokines in melanoma immune response, we estimated the proportions of immune cell subsets in melanoma tumors from The Cancer Genome Atlas, followed by evaluation of the association between cytokine/chemokine expression and these subsets. We then investigated the association of immune cell subsets, chemokines, and cytokines with patient survival. Finally, we evaluated the immune cell tumor-infiltrating lymphocyte (TIL) score for correlation with melanoma patient outcome in a separate cohort. There was good agreement between RNA sequencing estimation of T-cell subset and pathologist-determined TIL score. Expression levels of cytokines IL-12A, IFNG, and IL-10, and chemokines CXCL9 and CXCL10 were positively correlated with PDCD1, CTLA-4, and CD8+ T-cell subset, but negatively correlated with tumor purity (Bonferroni-corrected P < 0.05). In multivariable analysis, higher expression levels of cytokines IFN-γ and TGFB1, but not chemokines, were associated with improved overall survival. A higher expression level of CD8+ T-cell subset was also associated with improved overall survival (hazard ratio [HR] = 0.06, 95% confidence interval [CI] = 0.01-0.35, P = 0.002). Finally, multivariable analysis showed that patients with a brisk TIL score had improved melanoma-specific survival than those with a nonbrisk score (HR = 0.51, 95% CI = 0.27-0.98, P = 0.0423). These results suggest that the expression of specific tumor cytokines represents important biomarkers of melanoma immune response.
引用
- Fang S, Xu T, Xiong M, et al. Role of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines/Chemokines in Melanoma Progression. J Invest Dermatol. 2019. PMID: 31176707. doi:10.1016/j.jid.2019.03.1158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。